SCHEMBL4549023

SCHEMBL4549023

Cc1cc(C(=O)O)ccc1CO

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACE2 Q9BYF1 3/20 0.53
EPHX2 P34913 1/20 0.53
ALDH1A1 P00352 2/20 0.51
KDM4E B2RXH2 1/20 0.51
GAA P10253 1/20 0.51
L3MBTL1 Q9Y468 1/20 0.51
TSHR P16473 2/20 0.49
MYC P01106 1/20 0.49
ESR1 P03372 1/20 0.49
ALOX15 P16050 1/20 0.49
PTPN7 P35236 1/20 0.49
HSD17B10 Q99714 1/20 0.49
GRM1 Q13255 2/20 0.47
TDP1 Q9NUW8 2/20 0.47
MEN1 O00255 1/20 0.47
CYP1A2 P05177 1/20 0.47
KMT2A Q03164 1/20 0.47
NR1H4 Q96RI1 1/20 0.46
TPMT P51580 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6859659 0.86 EPHX2 (0.54) EPHX2ALDH1A1KDM4EGAAL3MBTL1
SCHEMBL2591830 0.86 EPHX2 (0.54) EPHX2ALDH1A1KDM4EGAAL3MBTL1
SCHEMBL8028194 0.85 RXRA (0.53) ACE2KDM4EHSD17B10RXRARARB
SCHEMBL5223897 0.85 EPHX2 (0.50) ACE2EPHX2ALDH1A1KDM4EGAA
SCHEMBL11427122 0.84 PKM (0.52) ACE2ALDH1A1KDM4EGAAL3MBTL1
SCHEMBL1909365 0.84 PKM (0.61) ALDH1A1L3MBTL1HSD17B10TDP1KMT2A
SCHEMBL14235189 0.82 NR1H4 (0.52) EPHX2ALDH1A1KDM4EGAAL3MBTL1
SCHEMBL11423248 0.82 EPHX2 (0.51) EPHX2ALDH1A1KDM4EGAAL3MBTL1
SCHEMBL3360458 0.82 EPHX2 (0.51) ACE2EPHX2ALDH1A1KDM4EGAA
SCHEMBL6439247 0.82 EPHX2 (0.51) ACE2EPHX2ALDH1A1KDM4EGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-105001298-A Synthesis-separation and purification method for indissolvable polypeptide SPEC CHEM INDUSTRY INC 2015-10-28 CN claimed
CN-105001307-A Coupling peptide chain capable of dissolving indissolvable polypeptide and application of the same in separation and purification in liquid chromatogram SPEC CHEM INDUSTRY INC 2015-10-28 CN claimed
CN-114163162-B Mineral powder hardening grinding aid and grinding-aid process thereof 常州坚鹏建材有限公司 2022-08-09 CN disclosed
CN-114163162-A Mineral powder hardening grinding aid and grinding-aid process thereof 常州坚鹏建材有限公司 2022-03-11 CN disclosed
EP-2766360-B1 SOLUBLE GUANYLATE CYCLASE ACTIVATORS BOEHRINGER INGELHEIM INT (DE) 2017-07-12 EP disclosed
US-9670231-B2 Fused tricyclic amide compounds as multiple kinase inhibitors BEIGENE, LTD. (KY) 2017-06-06 US disclosed
US-9670231-B2 Fused tricyclic amide compounds as multiple kinase inhibitors BEIGENE, LTD. (KY) 2017-06-06 US disclosed
CN-105531269-A \"inhibitors of nicotinamide phosphoribosyltransferase, compositions, products and uses thereof\ UNIV DEGLI STUDI DEL PIEMONTE ORIENTALE AMEDEO AVOGADRO 2016-04-27 CN disclosed
CN-105001307-A Coupling peptide chain capable of dissolving indissolvable polypeptide and application of the same in separation and purification in liquid chromatogram SPEC CHEM INDUSTRY INC 2015-10-28 CN disclosed
CN-105001298-A Synthesis-separation and purification method for indissolvable polypeptide SPEC CHEM INDUSTRY INC 2015-10-28 CN disclosed
CN-104822678-A Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity CHIESI FARMA SPA 2015-08-05 CN disclosed
US-8815857-B2 Soluble guanylate cyclase activators BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2014-08-26 US disclosed
US-8815857-B2 Soluble guanylate cyclase activators BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2014-08-26 US disclosed
US-20130203729-A1 SOLUBLE GUANYLATE CYCLASE ACTIVATORS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-08-08 US disclosed
US-20130203729-A1 SOLUBLE GUANYLATE CYCLASE ACTIVATORS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-08-08 US disclosed
CN-103209969-A Functionalised antifouling compounds and use thereof AGENCY SCIENCE TECH & RES 2013-07-17 CN disclosed
WO-2013025425-A1 SOLUBLE GUANYLATE CYCLASE ACTIVATORS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-02-21 WO disclosed
WO-2012055482-A1 NON-METAL TANNING PROCESS CLARIANT INTERNATIONAL LTD (CH) 2012-05-03 WO disclosed
WO-2012055483-A1 NON-METAL TANNING PROCESS CLARIANT INTERNATIONAL LTD (CH) 2012-05-03 WO disclosed
CN-1215404-A Non-dendritic backbone piptide carrier PEPRESEACH A S (DK) 1999-04-28 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130203729-A1 SOLUBLE GUANYLATE CYCLASE ACTIVATORS GUCY1A2, GUCY1A1, GUCY1B1 ACE2 1818/4885EPHX2 612/4885ALDH1A1 1347/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.